Topin & Associates for Dusa's ClindaReach
Pharmaceutical Executive
ClindaReach, from Dusa Pharmaceuticals, offers a simple and practical solution for patients with acne in hard-to-reach places: ClindaReach, an application wand.
REACH BACK
Topin & Associates
BRAND ClindaReach CLIENT Dusa Pharmaceuticals FROM LEFT: John Diaz, vice president, creative director; Michelle Rigot, copywriter
ClindaReach, from Dusa Pharmaceuticals, offers a simple and practical solution for patients with acne in hard-to-reach places: ClindaReach, an application wand.
Dermatologists are used to seeing ads featuring before-and-after photographs of smiling patients. But Dusa asked Topin to push the envelope. "The product is unique, so the client wanted to see something that was really different from other products and ads," says John Diaz, vice president, creative director.
Topin & Associates was charged with creating the launch campaign for the drug and demonstrating—in a simple iconic image—the benefit. But they also added a little humor with an interactive element. The creative produced by the agency first illustrated the hard-to-reach in an amusing way, and then let the audience reveal the ClindaReach solution by lifting a flap on the ad.
According to Diaz, the lighthearted depiction of the problem and visualization of the solution really connected with dermatologists, and created an extremely positive response.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
